Sustainability teams must increasingly prove not just that they reduce harm, but that they create value. From impact valuation to avoided-cost models, which frameworks are converting metrics into value creation, and which survive contact with a CFO? This session explores how sustainability data is shaping procurement, product design and capital allocation.

Resilience and sustainability often run as separate programmes, yet the same shocks threaten both: energy price spikes, water scarcity, extreme weather and supplier failure. With heat-stressed hospitals and disrupted cold chains making adaptation as urgent as mitigation, this session explores how organisations fold sustainability into resilience planning, and where the two agendas reinforce each other.

Circularity is straightforward in principle but fiendish in practice and looks different across the value chain: from raw materials and bioprocessing to next-generation propellants, devices, packaging and end-of-life recovery. This session examines ecodesign, take-back schemes, material choices, and regulatory hurdles, and asks how to deliver greener products without compromising performance or patient care.

Most of pharma's footprint sits with suppliers, who are hearing the same requests from every customer. With the NHS Supplier Roadmap and pharma procurement policies setting hard expectations, how do you manage suppliers to drive action rather than data collection? This panel explores incentives, shared standards, consortium approaches and what moves the needle for smaller suppliers.

Pharma has more sustainability data than it can use, and AI promises to crunch it, turning product carbon metrics into real-time decisions. But the technology behind that promise has its own energy and water footprint. Can pharma deploy AI and automation for genuine net environmental benefit, rather than shifting impact from lab to data centre?